secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2022-10-13T23:59:59+00:00
Accession:  0001193125-22-262210
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara to merge with Enliven; Enliven stockholders to own ~84% of combined company
--------------------------------------------------------------------------------

- Enliven valued at $324.6M plus $164.5M financing; Imara valued at net cash plus $10M.
- Pre-merger Imara stockholders to own ~16% of combined co; CVRs tied to asset sale/IMR-261.
- Concurrent $164.5M Enliven PIPE; closing conditioned on Imara asset sale, HSR, stockholder votes.
- Board: 8 Enliven designees, 1 Imara (CEO Rahul Ballal); reverse stock split planned.
- Termination fees: Imara pays $3M, Enliven pays $9.75M under specified conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312522262210/0001193125-22-262210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312522262210/d343665d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-262210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer